Coherus Oncology (CHRS) Acquisitions (2014)

Coherus Oncology's (CHRS) quarterly Acquisitions came in at $2.3 million in Q1 2014.

Coherus Oncology (CHRS) Acquisitions (2014) Analysis & Trends

Coherus Oncology has disclosed Acquisitions across 1 years of filings, most recently posting $2.3 million for Q1 2014.

Acquisitions for Q1 2014 came in at $2.3 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2014 was $2.3 million (changed N/A YoY), and the FY2023 annual result was $7.0 million, changed N/A from the prior year.
Acquisitions came in at $2.3 million for Q1 2014 at Coherus Oncology.
In the past five years, Acquisitions ranged from a high of $2.3 million in Q1 2014 to a low of $2.3 million in Q1 2014.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Coherus Oncology	199.14 Mn	32.09 Mn	8.50 Mn	-

Historic Data

Download Data

Date	Value
Mar 31, 2014	2.33 Mn